StoneX Group’s Catheter Precision VTAK Stock Holding History

StoneX Group’s Portfolio VTAK Stock Details VTAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	-$4.4K	–	516
2022 Q2	$4.4K	Buy	+1	New	+$3.09K	﹤0.01%	485

Other funds holding VTAK

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSG

Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

APP

Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

StoneX Group's VTAK Position: Q3 2022 in Review

StoneX Group sold out of Catheter Precision (VTAK) in Q3 2022, closing a stake of 1 share — an estimated $4.4K sold.

StoneX Group first reported a position in VTAK in Q2 2022 and held it in 1 quarter. The position peaked at $4.4K in Q2 2022. 17 funds tracked by Wall St. Rank hold VTAK as of Q3 2022.

StoneX Group reported no remaining Catheter Precision position as of Q3 2022 after selling out during the quarter.
StoneX Group sold 1 Catheter Precision share in Q3 2022, an estimated $4.4K.
StoneX Group first reported a position in Catheter Precision in Q2 2022 and held it in 1 quarter.
StoneX Group's Catheter Precision position peaked at $4.4K in Q2 2022.
17 funds tracked by Wall St. Rank held Catheter Precision as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.